| Intrinsic Valuation of: AMBUJACEM | |||||||||||
| Free Cash Flow Average and Growth over past 5Y | Key Statistics | ||||||||||
| Year | FCF | FCF (FCF/Revenue) | |||||||||
| 2020 | - | - | EPS (FY) | 17 | Market Cap | ₹1,429B | |||||
| 2021 | - | - (-) | P/E Ratio | 34 | Total Asset | ₹809B | |||||
| 2022 | ₹31B | - (-) | Net Income | ₹42B | Total Debt | ₹144M | |||||
| 2023 | ₹30B | -4.0% (-19.0%) | EBITDA | ₹86B | Total Liab | ₹171B | |||||
| 2024 | ₹12B | -60.9% (-66.0%) | Opr Margin | 0.10 | Debt/Equity | 0.00 | |||||
| 2025 | ₹-64B | -654.4% (-639.8%) | PreTax Margin | 9.72 | BV/Share | 150 | |||||
| 5Y Average FCF | ₹2B | -239.8% (-241.6%) | |||||||||
| Overall Market Assumptions: | |||||||||||
| Assumptions: | P/E for No-Growth Company: | 7.0 | |||||||||
| Perpetual Growth Rate (g): | 2.5% | Historical US Bond Yield: | 4.4% | ||||||||
| Discount Rate (WACC): | 7.4% | Current US Bond Yield: | 3.5% | ||||||||
| Forcasting Future Free Cash Flow for next 6Y | Modified Benjamin Graham's Intrinsic Value | ||||||||||
| Year | FCF Projection (4.0%) | ||||||||||
| 2026 | ₹2B | MBG Intrinsic Value | ₹153 | ||||||||
| 2027 | ₹2B | ||||||||||
| 2028 | ₹2B | ||||||||||
| 2029 | ₹2B | ||||||||||
| 2030 | ₹2B | ||||||||||
| 2031 | ₹2B | ||||||||||
| Terminal Value | ₹52B | Net Worth/Share | ₹259 | ||||||||
| DCF Valuation | DCF Valuation "What If" Scenario Table | ||||||||||
| Enterprise Value | ₹44B | Growth Rate | |||||||||
| (+) Cash & Cash Equivalents | ₹50B | ₹38 | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | ||||
| (-) Total Debt | ₹144M | WACC | 7.3% | 36 | 37 | 39 | 40 | 43 | |||
| Equity Value | ₹95B | 7.4% | 36 | 37 | 39 | 40 | 42 | ||||
| Shares Outstanding | 2,463,119,872 | 7.4% | 36 | 37 | 38 | 40 | 42 | ||||
| 7.9% | 35 | 36 | 37 | 38 | 40 | ||||||
| DCF Intrinsic Value | ₹38 | 8.4% | 34 | 34 | 35 | 36 | 38 | ||||
| Analyzed by QuantJuice (2025) | |||||||||||